{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:43:19Z","timestamp":1783456999875,"version":"3.55.0"},"reference-count":34,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In the race for a vaccine against SARS-CoV-2, the synthetic mRNA format has been shown to be the fastest one and proved to be safe and highly efficient, even at the very low dose of a few \u00b5g per injection. The mRNA vaccines are not new: vaccines that are based on attenuated mRNA viruses, such as Mumps, Measles, and Rubella, immunize by delivering their mRNAs into the cells of the vaccinated individual, who produces the viral proteins that then prime the immune response. Synthetic mRNA in liposomes can be seen as a modern, more refined, and thereby a safer version of those live attenuated RNA viruses. The anti-COVID-19 mRNA vaccine (coding the SARS-CoV-2 spike protein) is the third synthetic RNA therapeutic being approved. It follows the aptamer Macugen\u00ae (which neutralizes VEGF) and the siRNA Onpattro\u00ae (which destroys the transthyretin-coding mRNA). Remarkably, the 30 \u00b5g of mRNA that are contained in the first approved anti-COVID-19 vaccine are sufficient for generating high levels of neutralizing antibodies against the virus in all injected volunteers (including participants over 65 years old). The efficacy and safety data are stunning. The distribution of these vaccines throughout the world will bring a halt to the coronavirus pandemic.<\/jats:p>","DOI":"10.3390\/v13020270","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T10:01:05Z","timestamp":1613296865000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2946-5576","authenticated-orcid":false,"given":"Steve","family":"Pascolo","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Z\u00fcrich, Gloriastrasse 31, 8091 Z\u00fcrich, Switzerland"},{"name":"Faculty of Medicine, University of Z\u00fcrich, 8091 Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/319618a0","article-title":"Origin of life: The RNA world","volume":"319","author":"Gilbert","year":"1986","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1517\/14712598.4.8.1285","article-title":"Messenger RNA-based vaccines","volume":"4","author":"Pascolo","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_3","first-page":"23","article-title":"Vaccination with messenger RNA","volume":"127","author":"Pascolo","year":"2006","journal-title":"Methods Mol. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pascolo, S. (2008). Vaccination with messenger RNA (mRNA). Handb. Exp. Pharmacol., 221\u2013235.","DOI":"10.1007\/978-3-540-72167-3_11"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2014Developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_8","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.gt.3302964","article-title":"Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent","volume":"14","author":"Probst","year":"2007","journal-title":"Gene Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/mt.2010.289","article-title":"Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients","volume":"19","author":"Rittig","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: Results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1099\/vir.0.80907-0","article-title":"Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells","volume":"86 Pt 9","author":"Ceppi","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1007\/s00018-004-4255-0","article-title":"Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines","volume":"61","author":"Carralot","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/eji.200324198","article-title":"Immunostimulating capacities of stabilized RNA molecules","volume":"34","author":"Scheel","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/eji.200425656","article-title":"Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA","volume":"35","author":"Scheel","year":"2005","journal-title":"Eur. J. Immunol"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-0556-3-6","article-title":"Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas","volume":"3","author":"Carralot","year":"2005","journal-title":"Genet. Vaccines Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e1108511","DOI":"10.1080\/2162402X.2015.1108511","article-title":"Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy","volume":"5","author":"Rittig","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I\/IIa study","volume":"3","author":"Scheel","year":"2015","journal-title":"J. Immunothe.r Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Elfakess, R., and Dikstein, R. (2008). A translation initiation element specific to mRNAs with very short 5\u2019UTR that also regulates transcription. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003094"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1093\/nar\/gkz261","article-title":"Charting DENR-dependent translation reinitiation uncovers predictive uORF features and links to circadian timekeeping via Clock","volume":"47","author":"Tusup","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tusup, M., Kundig, T., and Pascolo, S. (2018). An eIF4G-recruiting aptamer increases the functionality of in vitro transcribed mRNA. Int. J. Med. Health Sci., 4.","DOI":"10.53555\/eijmhs.v4i2.36"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41587-019-0164-5","article-title":"Human 5\u2032 UTR design and variant effect prediction from a massively parallel translation assay","volume":"37","author":"Sample","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"ref_30","first-page":"824","article-title":"Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3\u2032 UTRs Identified by Cellular Library Screening","volume":"27","author":"Poleganov","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Buschmann, M.D., Carrasco, M.J., Alishetty, S., Paige, M., Alameh, M.G., and Weissman, D. (2021). Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9010065"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/2\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:22:11Z","timestamp":1760160131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/2\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["v13020270"],"URL":"https:\/\/doi.org\/10.3390\/v13020270","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]}}}